Cardiac Dysfunction in Critically Ill Patients With COVID-19

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04524234

Acronym

CARDYCOVID

Enrollment

132

Registered

2020-08-24

Start date

2020-04-20

Completion date

2020-09-30

Last updated

2020-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19, Left Ventricular Dysfunction, Pulmonary Hypertension, Right Ventricular Dysfunction

Brief summary

Detailed description

Cardiac dysfunction has been reported to be common in patients infected with COVID-19. The aim of this study is to evaluate the clinical importance of cardiac dysfunction in critically ill patients with COVID-19. Patients admitted to the intensive care unit, with COVID-19 are examined with echocardiography for assessment of left and right ventricular dysfunction within 72 hours from admission and repeated after four to seven days. Cardiac dysfunction was defined as having either left ventricular (LV) dysfunction, defined as having an ejection fraction \<50% and/or regional hypokinesia, or right ventricular (RV) dysfunction, defined as having a tricuspid annular plane excursion (TAPSE) \<17mm or a moderate/severe RV dysfunction assessed visually. The cardiac biomarkers troponin and NTproBNP and clinical data are recorded at time of each echo. Mortality status is recorded at 30 days.

Interventions

DIAGNOSTIC_TESTEchocardiography

Echocardiography for assessment of cardiac function

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Inclusion criteria

Patients admitted to the intensive care unit infected with COVID-19

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
Mortality	30 days	All cause death in patients with vs without cardiac dysfunction

Secondary

Measure	Time frame	Description
Left ventricular dysfunction	Within 72 hours from admission	Prevalence of left ventricular dysfunction
Right ventricular dysfunction	Within 72 hours from admission	Prevalence of right ventricular dysfunction
Risk-factors	Within 72 hours from admission	Clinical variables associated with risk of having cardiac dysfunction
Cardiac biomarkers	Within 72 hours from admission	Levels of cardiac biomarkers in patients with vs without cardiac dysfunction

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026